BUSINESS-WIRE
2.4.2018 15:02:08 CEST | Business Wire | Press release
Business Wire and TrendKite have entered into a reciprocal sales arrangement, enabling clients to leverage the industry’s most comprehensive news distribution platform and then gauge the effectiveness of their campaign using the advanced analytics of TrendKite’s Intelligent Communications Platform .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180402005104/en/
The agreement brings together two influential service providers serving the public relations industry: Business Wire, the global leader in press release distribution, and TrendKite, a startup that has upended the legacy monitoring industry with its technological innovation and data-driven approach to quantifying media outreach results.
Business Wire and TrendKite will offer select service offerings under the terms of the agreement.
TrendKite clients will have the opportunity to reach audiences worldwide via Business Wire, which provides access to dozens of international and national news agencies, as well as leading financial information platforms, news syndicators, content aggregation services and databases.
Business Wire clients will be able to take advantage of the TrendKite Intelligent Communications Platform to measure the effectiveness of their press releases and public relations campaigns and identify and target key journalists and influencers to pitch. TrendKite helps organizations make better data-informed decisions about their communications programs and measure the business impact and bottom line results of their earned media. TrendKite’s innovative services transform 4.7 million global sources into actionable intelligence with customized dashboards, interactive reports, social amplification, Google and Adobe Analytics integrations and PR Attribution , which assesses the true impact of a media mention by measuring site traffic influenced by earned media. Going a step further, TrendKite has created Pinpoint Contacts, an artificial intelligence-powered influencer and journalist database, to assist communicators in identifying relevant contacts.
“TrendKite is a forward-thinking company that is aligned with Business Wire’s perspective on the future of content delivery and monitoring solutions,” said Geff Scott , Business Wire’s chief executive officer. “Our relationship with TrendKite promises to bring value to clients of both companies, providing best-of-breed solutions that will create new industry standards.”
“Our customers rely on news distribution as part of their plan to take a story to market, but have trouble knowing if their press releases are gaining earned coverage that drives business results,” said Erik Huddleston, TrendKite’s chief executive officer. “Business Wire’s status as the industry leader, combined with their measurably superior results and their understanding of the earned media landscape, make them a natural partner for TrendKite and a high value for our customers.”
About Business Wire:
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure . Investor relations, public relations, public policy and marketing professionals rely on Business Wire to accurately distribute market-moving news and multimedia, host online newsrooms and IR websites , build content marketing platforms , generate social engagements and provide audience analysis that improves interaction with specified target markets. Founded in 1961, Business Wire is a trusted source for news organizations, journalists, investment professionals and regulatory authorities, delivering news directly into editorial systems and leading online news sources via its multi-patented NX Network. Business Wire has 29 offices worldwide to securely meet the varying needs of communications professionals and news consumers.
Learn more at services.BusinessWire.com and Tempo , the Business Wire resource for industry trends; follow updates on Twitter: @businesswire or on Facebook .
About TrendKite
Founded in 2012 in Austin, Texas, TrendKite is the Intelligent Communications Platform that puts earned media at the heart of the marketing mix. By harnessing artificial intelligence and big data analytics to optimize the impact public relations has on a brand’s reputation, website traffic and business goals, TrendKite is transforming the way the world views earned media.
As a venture backed, high traction startup, TrendKite is disrupting a huge existing market while helping companies like Nike, Google, Delta, SXSW and thousands more turn PR coverage into real business impact.
Click here to subscribe to Mobile Alerts for Business Wire .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180402005104/en/
Contact:
TrendKite
Lacey Miller
lacey@trendkite.com
or
Business
Wire
Neil Hershberg, +1 212-752-9600, Ext. 1434
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom